Teva launches generic Uceris
Teva Pharmaceuticals Industries has introduced the generic version of Salix Pharmaceuticals’ Uceris (budesonide) extended-release tablets in a 9 mg dosage strength.
Budesonide extended-release tablets are a glucocorticosteroid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.
“The launch of generic budesonide extended-release tablets signals an important addition to Teva’s portfolio,” said Teva executive vice president and head of North America Commercial Brendan O’Grady. “We continue to be focused on bringing affordable generic treatment options to our customers, including those living with chronic, life-long conditions like ulcerative colitis.”
Uceris has a market value of approximately $196 million in the United States, according to IMS data as of May 2018.
Lupin receives FDA nod for generic Plaquenil tablets
Lupin has received the green light from the Food and Drug Administration for a generic version of Concordia Pharmaceuticals’ Plaquenil tablets, 200 mg. (hydroxychloroquine sulfate tablets, 200 mg).
The product is indicated for the treatment of uncomplicated malaria due to P. falciparum, P. malariae, P. ovale and P. vivax; the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported; the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults; and the treatment of acute and chronic rheumatoid arthritis in adults.
The product’s market size for the 12 months ended April 2018 was $215.3 million, according to IQVIA data.
Mylan expands central nervous system portfolio with generic Exelon patch
Mylan has received the green light from the Food and Drug Administration for a generic version of Novartis’ Exelon Patch (rivastigmine transdermal system). The product is indicated for the treatment of dementia associated with mild, moderate and severe Alzheimer’s disease and the treatment of mild-to-moderate dementia associated with Parkinson’s disease.
The generic Exelon patch is available in 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs.
“The launch of generic Exelon Patch is another example of the investment Mylan is continuing to make into products that are difficult to develop and manufacture, particularly in transdermal drug delivery systems. The launch of this product also strengthens the company’s growing central nervous system portfolio, which is a therapeutic area of continued focus for Mylan as we strive to provide better health for a better world,” said Mylan president Rajiv Malik.